Related Experiment Video
Updated: Jun 13, 2026

Using the Activity-based Anorexia Rodent Model to Study the Neurobiological Basis of Anorexia Nervosa
Published on: October 22, 2015
Pharmacotherapy of eating disorders
Cherry Wyant Jackson1, Marshall Cates, Raymond Lorenz
1University of Alabama, Birmingham, AL 35294-0018, USA. cwj0002@auburn.edu
Abstract:
Eating disorders are complex, chronic disorders that are difficult to treat. In addition, the 2 primary eating disorders, anorexia nervosa and bulimia nervosa, may have acute, life-threatening consequences. Medication trials for eating disorders have been hampered by high dropout rates, high placebo response, short trial duration, insufficient doses, and difficult outcome measures. Only 1 medication has been FDA approved for any eating disorder to date, and that is for fluoxetine in the treatment of bulimia. Clearly, new large-scale, independent studies using novel agents, and studying the use of medications for both short- and long-term outcomes, are needed.
Related Concept Videos
Binge Eating Disorders
Bulimia Nervosa
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: MAOIs and Other Agents
Anorexia Nervosa
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...

